Previous 10 | Next 10 |
Editor's note: Seeking Alpha is proud to welcome Boston Biotech Investor as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Essential. Click here to find out more » In my 3...
Initially, TheraupeticsMD ( TXMD ) was more of a trading idea than an investment as I was bullish on approval for Imvexxy and Bijuva. My trading thesis at that time was no additional trial was required for Imvexxy and Bijuva would be approved with no hiccup. The thesis was validated, but I...
Initially, TheraupeticsMD ( TXMD ) was more of a trading idea than an investment as I was bullish on approval for Imvexxy and Bijuva. My trading thesis at that time was no additional trial was required for Imvexxy and Bijuva would be approved with no hiccup. The thesis was validated, but I...
Gainers: Jaguar Health (NASDAQ: JAGX ) +60% . ContraVir Pharmaceuticals (NASDAQ: CTRV ) +40% . TORM (NASDAQ: TRMD ) +20% . Rekor Systems, Inc. (REKR) +17% . Enzo Biochem, Inc. (NYSE: ENZ ) +17% . Oxbridge Re Holdings (NASDAQ: OXBR ) +16% . Tenax Therapeutics (NASDAQ: TENX ) +1...
TherapeuticsMD ( TXMD -4.6% ) is down on more than 60% higher volume in apparent response to its 2019 guidance released during its investor event today. More news on: TherapeuticsMD, Inc., Healthcare stocks news, Stocks on the move, Read more ...
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, will host its Investor and Analyst Day today in New York City. Members of TherapeuticsMD’s management team and key opinion leaders will provide updates on the company’s ...
TherapeuticsMD (NASDAQ: TXMD ) has agreed to out-license the ex-U.S. rights (except Canada and Israel) to BIJUVA (estradiol and progesterone capsules) and IMVEXXY (estradiol vaginal inserts) to CVC Capital Partners' Theramex. More news on: TherapeuticsMD, Inc., Healthcare stocks news, St...
-Agreement leverages Theramex’s extensive women’s health capabilities and infrastructure to the benefit of menopausal women outside of U.S.- -TherapeuticsMD to receive EUR 14 million as an upfront fee and is eligible to receive up to EUR 29.5 million in regulatory and sales ...
TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative, leading women’s healthcare company, today announced that it will host an Investor and Analyst Day on Monday, June 10, 2019, in New York City. Members of TherapeuticsMD’s management team and key opinion leader...
Short interest is often seen as a poor indicator for future price performance because it can represent conflicting signals. One one hand, its backward-looking as the stocks with the weakest operating and financial results typically decline against the market attracting further speculative sell...
News, Short Squeeze, Breakout and More Instantly...
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Net Income (...
• Evaluation of strategic alternatives continues TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023...